Statin Market was valued US$ 14.95 Bn in 2022 and is expected to reach US$ 18.39 Bn by 2029, at a CAGR of 3% during a forecast period. Statins are used for prevention and treatment for atherosclerosis, which causes chest pain, heart attacks, and strokes. It is mostly prescribed to lower down the low density lipoprotein cholesterol in the body and helps to reduce mortality in high risk patients.To know about the Research Methodology :- Request Free Sample Report
Statin Market Dynamics:
An increase in prevalence of cholesterol due to changing lifestyle are expected to increase the demand for statins across the globe. Sedentary lifestyle across the developed regions is one of the key drivers of the global market. The bad cholesterol is difficult to manage by diet and exercise, the statins are highly recommended to treat the condition. In addition, Cholesterol awareness campaigns and technologically advanced health care facilities are increasing the demand for statins. The rapid pace of urbanisation is leading to cholesterol-related disorders and ensuring sustained demand for statins. Cholesterol consciousness and technologically forward health administration amenities are some of the prominent factors behind the market growth. Despite the presence of the prominent driving factors, the requirement for adequate remedy options serves is expected to limit the global station market. The cultural and commercial agents and Side effects of statins are also expected to hamper the growth of the statin business.Statin Market Segment Analysis:
In the global statin market, there are many different statin molecules like simvastatin, pravastatin, lovastatin and atorvastatin are present. The Simvastatin, lovastatin and pravastatin together have annual sales of more than $10 Bn globally. Among these, Lovastatin is already off patent across the globe and simvastatin and pravastatin are off patent in Europe.High low-density lipoprotein cholesterol is one of the modifiable risk factors for atherosclerotic cardiovascular disease. An increase in the number of patients, who are suffering from cardiovascular diseases are expected to increase the demand for statins across the globe. In the U.S., One person dies every 36 seconds from cardiovascular disease. It statins are widely used to reduce adverse cardiovascular outcomes. Despite the older individuals have the highest absolute risk for atherosclerotic cardiovascular disease, the US guidelines for blood pressure and cholesterol have recommended lower-intensity treatment strategies that are expected to drive the market growth. The Hospitals segment is expected to hold the dominant position in the global market. The dominant position in the market is attributed to the increased requirement for treatment of cardiovascular disorders and inflammatory disorders treatments. The healthcare providers are focusing on the enhancement of the patient admission capacities at hospitals, number of medical professionals and availability of the drugs for reduction of the cholesterol.
Statin Market Regional Analysis:
North America region held the dominant position in 2022 and is projected to continue its dominance during the forecast period. The market growth attribute to the presence of the number of cardiovascular disorders affected people and prominent healthcare service providers. An increase in occurrence of obesity, cardiovascular diseases and diabetes among old populations are expected to drive the demand for effective treatment of high cholesterol. In America, more than 70% American adults are suffering from LDL cholesterol. The American College of Cardiology and the American Heart Association have announced the guidelines that people with 7.5% or higher risk for heart attack have to be prescribed statins, which is expected to double statin usage in the US and Canada. The statins market has proved to be a lucrative and profitable market for the key players in the region. Consumption of statins is high among geriatrics population that is expected to boost the market growth in the near future.Statin Market Competitive Analysis:
Some of the prominent key players like Abbott, AstraZeneca and Aurobindo Pharma are expanding their market presence across the globe by establishing strong distribution networks, mainly in developing countries. Furthermore, Indian pharmaceutical companies are also exciting to get a foothold in the global statins market. For instance, Big Indian pharmaceutical companies like Ranbaxy Laboratories and Lupin Laboratories are concentrating to form the their footprint in the statins market. The Indian key players are expect to take benefits by marketing statin generics. The objective of the report is to present a comprehensive analysis of the global market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding global market dynamics, structure by analyzing the market segments and projects the global market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the global market make the report investor’s guide.Scope of the Statin Market: Inquire before buying
Statin Market Base Year 2022 Forecast Period 2023-2029 Historical Data CAGR Market Size in 2022 Market Size in 2029 2018 to 2022 3% US$ 14.95 Bn US$ 18.39 Bn Segments Covered by Drug Class Astrovastatin Fluvastatin Lovastatin Pravastatin Simvastatin Others by Therapeutic Treatment Cardiovascular disorders Obesity Inflammatory disorders Others by End User Hospitals Clinics Regions Covered North America United States Canada Mexico Europe UK France Germany Italy Spain Sweden Austria Rest of Europe Asia Pacific China S Korea Japan India Australia Indonesia Malaysia Vietnam Taiwan Bangladesh Pakistan Rest of APAC Middle East and Africa South Africa GCC Egypt Nigeria Rest of ME&A South America Brazil Argentina Rest of South America Statin Market Key players are:
1. Abbott 2. AstraZeneca 3. Aurobindo Pharma 4. Biocon 5. GlaxoSmithKline 6. Merck & Co. 7. Novartis 8. Pfizer 9. Bayer 10.Amgen Inc. 11.Concord Biotech Frequently Asked Questions: 1. Which region has the largest share in Global Statin Market? Ans: North America region holds the highest share in 2022. 2. What is the growth rate of Global Statin Market? Ans: The Global Statin Market is growing at a CAGR of 3% during forecasting period 2023-2029. 3. What segments are covered in Global Statin market? Ans: Statin Market is segmented into drug class, therapeutic treatment, end user and region. 4. Who are the key players in Global Statin market? Ans: The important key players in the Statin Market are – Abbott, AstraZeneca, Aurobindo Pharma, Biocon, GlaxoSmithKline, Merck & Co., Novartis, Pfizer, Bayer, Amgen Inc., Concord Biotech 5. What is the study period of this market? Ans: The Global Statin Market is studied from 2022 to 2029.
Global Statin Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Statin Market Size, by Market Value (US$ Mn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Statin Market Analysis and Forecast 6.1. Statin Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Statin Market Analysis and Forecast, By Drug Class 7.1. Introduction and Definition 7.2. Key Findings 7.3. Statin Market Value Share Analysis, By Drug Class 7.4. Statin Market Size (US$ Mn) Forecast, By Drug Class 7.5. Statin Market Analysis, By Drug Class 7.6. Statin Market Attractiveness Analysis, By Drug Class 8. Global Statin Market Analysis and Forecast, By Therapeutic Treatment 8.1. Introduction and Definition 8.2. Key Findings 8.3. Statin Market Value Share Analysis, By Therapeutic Treatment 8.4. Statin Market Size (US$ Mn) Forecast, By Therapeutic Treatment 8.5. Statin Market Analysis, By Therapeutic Treatment 8.6. Statin Market Attractiveness Analysis, By Therapeutic Treatment 9. Global Statin Market Analysis and Forecast, By End User 9.1. Introduction and Definition 9.2. Key Findings 9.3. Statin Market Value Share Analysis, By End User 9.4. Statin Market Size (US$ Mn) Forecast, By End User 9.5. Statin Market Analysis, By End User 9.6. Statin Market Attractiveness Analysis, By End User 10. Global Statin Market Analysis, by Region 10.1. Statin Market Value Share Analysis, by Region 10.2. Statin Market Size (US$ Mn) Forecast, by Region 10.3. Statin Market Attractiveness Analysis, by Region 11. North America Statin Market Analysis 11.1. Key Findings 11.2. North America Statin Market Overview 11.3. North America Statin Market Value Share Analysis, By Drug Class 11.4. North America Statin Market Forecast, By Drug Class 11.4.1. Astrovastatin 11.4.2. Fluvastatin 11.4.3. Lovastatin 11.4.4. Pravastatin 11.4.5. Simvastatin 11.4.6. Others 11.5. North America Statin Market Value Share Analysis, By Therapeutic Treatment 11.6. North America Statin Market Forecast, By Therapeutic Treatment 11.6.1. Cardiovascular disorders 11.6.2. Obesity 11.6.3. Inflammatory disorders 11.6.4. Others 11.7. North America Statin Market Value Share Analysis, By End User 11.8. North America Statin Market Forecast, By End User 11.8.1. Hospital 11.8.2. Clinics 11.9. North America Statin Market Value Share Analysis, by Country 11.10. North America Statin Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Statin Market Analysis, by Country 11.12. U.S. Statin Market Forecast, By Drug Class 11.12.1. Astrovastatin 11.12.2. Fluvastatin 11.12.3. Lovastatin 11.12.4. Pravastatin 11.12.5. Simvastatin 11.12.6. Others 11.13. U.S. Statin Market Forecast, By Therapeutic Treatment 11.13.1. Cardiovascular disorders 11.13.2. Obesity 11.13.3. Inflammatory disorders 11.13.4. Others 11.14. U.S. Statin Market Forecast, By End User 11.14.1. Hospital 11.14.2. Clinics 11.15. Canada Statin Market Forecast, By Drug Class 11.15.1. Cardiovascular disorders 11.15.2. Obesity 11.15.3. Inflammatory disorders 11.15.4. Others 11.16. Canada Statin Market Forecast, By Therapeutic Treatment 11.16.1. Astrovastatin 11.16.2. Fluvastatin 11.16.3. Lovastatin 11.16.4. Pravastatin 11.16.5. Simvastatin 11.16.6. Others 11.17. Canada Statin Market Forecast, By End User 11.17.1. Hospital 11.17.2. Clinics 11.18. North America Statin Market Attractiveness Analysis 11.18.1. By Drug Class 11.18.2. By Therapeutic Treatment 11.18.3. By End User 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe Statin Market Analysis 12.1. Key Findings 12.2. Europe Statin Market Overview 12.3. Europe Statin Market Value Share Analysis, By Drug Class 12.4. Europe Statin Market Forecast, By Drug Class 12.4.1. Astrovastatin 12.4.2. Fluvastatin 12.4.3. Lovastatin 12.4.4. Pravastatin 12.4.5. Simvastatin 12.4.6. Others 12.5. Europe Statin Market Value Share Analysis, By Therapeutic Treatment 12.6. Europe Statin Market Forecast, By Therapeutic Treatment 12.6.1. Cardiovascular disorders 12.6.2. Obesity 12.6.3. Inflammatory disorders 12.6.4. Others 12.7. Europe Statin Market Value Share Analysis, By End User 12.8. Europe Statin Market Forecast, By End User 12.8.1. Hospital 12.8.2. Clinics 12.9. Europe Statin Market Value Share Analysis, by Country 12.10. Europe Statin Market Forecast, by Country 12.10.1. Germany 12.10.2. UK 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Norway 12.10.7. Russia 12.11. Europe Statin Market Analysis, by Country 12.12. Germany Statin Market Forecast, By Drug Class 12.12.1. Astrovastatin 12.12.2. Fluvastatin 12.12.3. Lovastatin 12.12.4. Pravastatin 12.12.5. Simvastatin 12.12.6. Others 12.13. Germany Statin Market Forecast, By Therapeutic Treatment 12.13.1. Cardiovascular disorders 12.13.2. Obesity 12.13.3. Inflammatory disorders 12.13.4. Others 12.14. Germany Statin Market Forecast, By End User 12.14.1. Hospital 12.14.2. Clinics 12.15. U.K. Statin Market Forecast, By Drug Class 12.15.1. Astrovastatin 12.15.2. Fluvastatin 12.15.3. Lovastatin 12.15.4. Pravastatin 12.15.5. Simvastatin 12.15.6. Others 12.16. U.K. Statin Market Forecast, By Therapeutic Treatment 12.16.1. Cardiovascular disorders 12.16.2. Obesity 12.16.3. Inflammatory disorders 12.16.4. Others 12.17. U.K. Statin Market Forecast, By End User 12.17.1. Hospitals 12.17.2. Clinics 12.17.3. Ambulatory Surgery Center 12.17.4. Other End Users 12.18. France Statin Market Forecast, By Drug Class 12.18.1. Astrovastatin 12.18.2. Fluvastatin 12.18.3. Lovastatin 12.18.4. Pravastatin 12.18.5. Simvastatin 12.18.6. Others 12.19. France Statin Market Forecast, By Therapeutic Treatment 12.19.1. Cardiovascular disorders 12.19.2. Obesity 12.19.3. Inflammatory disorders 12.19.4. Others 12.20. France Statin Market Forecast, By End User 12.20.1. Hospital 12.20.2. Clinics 12.21. Italy Statin Market Forecast, By Drug Class 12.21.1. Astrovastatin 12.21.2. Fluvastatin 12.21.3. Lovastatin 12.21.4. Pravastatin 12.21.5. Simvastatin 12.21.6. Others 12.22. Italy Statin Market Forecast, By Therapeutic Treatment 12.22.1. Cardiovascular disorders 12.22.2. Obesity 12.22.3. Inflammatory disorders 12.22.4. Others 12.23. Italy Statin Market Forecast, By End User 12.23.1. Hospital 12.23.2. Clinics 12.24. Spain Statin Market Forecast, By Drug Class 12.24.1. Astrovastatin 12.24.2. Fluvastatin 12.24.3. Lovastatin 12.24.4. Pravastatin 12.24.5. Simvastatin 12.24.6. Others 12.25. Spain Statin Market Forecast, By Therapeutic Treatment 12.25.1. Cardiovascular disorders 12.25.2. Obesity 12.25.3. Inflammatory disorders 12.25.4. Others 12.26. Spain Statin Market Forecast, By End User 12.26.1. Hospital 12.26.2. Clinics 12.27. Norway Statin Market Forecast, By Drug Class 12.27.1. Astrovastatin 12.27.2. Fluvastatin 12.27.3. Lovastatin 12.27.4. Pravastatin 12.27.5. Simvastatin 12.27.6. Others 12.28. Norway Statin Market Forecast, By Therapeutic Treatment 12.28.1. Cardiovascular disorders 12.28.2. Obesity 12.28.3. Inflammatory disorders 12.28.4. Others 12.29. Norway Statin Market Forecast, By End User 12.29.1. Hospital 12.29.2. Clinics 12.30. Russia Statin Market Forecast, By Drug Class 12.30.1. Astrovastatin 12.30.2. Fluvastatin 12.30.3. Lovastatin 12.30.4. Pravastatin 12.30.5. Simvastatin 12.30.6. Others 12.31. Russia Statin Market Forecast, By Therapeutic Treatment 12.31.1. Cardiovascular disorders 12.31.2. Obesity 12.31.3. Inflammatory disorders 12.31.4. Others 12.32. Russia Statin Market Forecast, By End User 12.32.1. Hospital 12.32.2. Clinics 12.33. Europe Statin Market Attractiveness Analysis 12.33.1. By Drug Class 12.33.2. By Therapeutic Treatment 12.33.3. By End User 12.34. PEST Analysis 12.35. Key Trends 12.36. Key Developments 13. Asia Pacific Statin Market Analysis 13.1. Key Findings 13.2. Asia Pacific Statin Market Overview 13.3. Asia Pacific Statin Market Value Share Analysis, By Drug Class 13.4. Asia Pacific Statin Market Forecast, By Drug Class 13.4.1. Astrovastatin 13.4.2. Fluvastatin 13.4.3. Lovastatin 13.4.4. Pravastatin 13.4.5. Simvastatin 13.4.6. Others 13.5. Asia Pacific Statin Market Value Share Analysis, By Therapeutic Treatment 13.6. Asia Pacific Statin Market Forecast, By Therapeutic Treatment 13.6.1. Cardiovascular disorders 13.6.2. Obesity 13.6.3. Inflammatory disorders 13.6.4. Others 13.7. Asia Pacific Statin Market Value Share Analysis, By End User 13.8. Asia Pacific Statin Market Forecast, By End User 13.8.1. Hospital 13.8.2. Clinics 13.9. Asia Pacific Statin Market Value Share Analysis, by Country 13.10. Asia Pacific Statin Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. South Korea 13.10.5. Australia 13.10.6. Malaysia 13.10.7. Indonesia 13.10.8. Vietnam 13.11. Asia Pacific Statin Market Analysis, by Country 13.12. China Statin Market Forecast, By Drug Class 13.12.1. Astrovastatin 13.12.2. Fluvastatin 13.12.3. Lovastatin 13.12.4. Pravastatin 13.12.5. Simvastatin 13.12.6. Others 13.13. China Statin Market Forecast, By Therapeutic Treatment 13.13.1. Cardiovascular disorders 13.13.2. Obesity 13.13.3. Inflammatory disorders 13.13.4. Others 13.14. China Statin Market Forecast, By End User 13.14.1. Hospital 13.14.2. Clinics 13.15. India Statin Market Forecast, By Drug Class 13.15.1. Astrovastatin 13.15.2. Fluvastatin 13.15.3. Lovastatin 13.15.4. Pravastatin 13.15.5. Simvastatin 13.15.6. Others 13.16. India Statin Market Forecast, By Therapeutic Treatment 13.16.1. Cardiovascular disorders 13.16.2. Obesity 13.16.3. Inflammatory disorders 13.16.4. Others 13.17. India Statin Market Forecast, By End User 13.17.1. Hospital 13.17.2. Clinics 13.18. Japan Statin Market Forecast, By Drug Class 13.18.1. Astrovastatin 13.18.2. Fluvastatin 13.18.3. Lovastatin 13.18.4. Pravastatin 13.18.5. Simvastatin 13.18.6. Others 13.19. Japan Statin Market Forecast, By Therapeutic Treatment 13.19.1. Cardiovascular disorders 13.19.2. Obesity 13.19.3. Inflammatory disorders 13.19.4. Others 13.20. Japan Statin Market Forecast, By End User 13.20.1. Hospital 13.20.2. Clinics 13.21. South Korea Statin Market Forecast, By Drug Class 13.21.1. Astrovastatin 13.21.2. Fluvastatin 13.21.3. Lovastatin 13.21.4. Pravastatin 13.21.5. Simvastatin 13.21.6. Others 13.22. South Korea Statin Market Forecast, By Therapeutic Treatment 13.22.1. Cardiovascular disorders 13.22.2. Obesity 13.22.3. Inflammatory disorders 13.22.4. Others 13.23. South Korea Statin Market Forecast, By End User 13.23.1. Hospital 13.23.2. Clinics 13.24. Australia Statin Market Forecast, By Drug Class 13.24.1. Astrovastatin 13.24.2. Fluvastatin 13.24.3. Lovastatin 13.24.4. Pravastatin 13.24.5. Simvastatin 13.24.6. Others 13.25. Australia Statin Market Forecast, By Therapeutic Treatment 13.25.1. Cardiovascular disorders 13.25.2. Obesity 13.25.3. Inflammatory disorders 13.25.4. Others 13.26. Australia Statin Market Forecast, By End User 13.26.1. Hospital 13.26.2. Clinics 13.27. Malaysia Statin Market Forecast, By Drug Class 13.27.1. Astrovastatin 13.27.2. Fluvastatin 13.27.3. Lovastatin 13.27.4. Pravastatin 13.27.5. Simvastatin 13.27.6. Others 13.28. Malaysia Statin Market Forecast, By Therapeutic Treatment 13.28.1. Cardiovascular disorders 13.28.2. Obesity 13.28.3. Inflammatory disorders 13.28.4. Others 13.29. Malaysia Statin Market Forecast, By End User 13.29.1. Hospital 13.29.2. Clinics 13.30. Indonesia Statin Market Forecast, By Drug Class 13.30.1. Astrovastatin 13.30.2. Fluvastatin 13.30.3. Lovastatin 13.30.4. Pravastatin 13.30.5. Simvastatin 13.30.6. Others 13.31. Indonesia Statin Market Forecast, By Therapeutic Treatment 13.31.1. Cardiovascular disorders 13.31.2. Obesity 13.31.3. Inflammatory disorders 13.31.4. Others 13.32. Indonesia Statin Market Forecast, By End User 13.32.1. Hospital 13.32.2. Clinics 13.33. Vietnam Statin Market Forecast, By Drug Class 13.33.1. Astrovastatin 13.33.2. Fluvastatin 13.33.3. Lovastatin 13.33.4. Pravastatin 13.33.5. Simvastatin 13.33.6. Others 13.34. Vietnam Statin Market Forecast, By Therapeutic Treatment 13.34.1. Cardiovascular disorders 13.34.2. Obesity 13.34.3. Inflammatory disorders 13.34.4. Others 13.35. Vietnam Statin Market Forecast, By End User 13.35.1. Hospital 13.35.2. Clinics 13.36. Asia Pacific Statin Market Attractiveness Analysis 13.36.1. By Drug Class 13.36.2. By Therapeutic Treatment 13.36.3. By End User 13.37. PEST Analysis 13.38. Key Trends 13.39. Key Developments 14. Middle East & Africa Statin Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Statin Market Overview 14.3. Middle East & Africa Statin Market Value Share Analysis, By Drug Class 14.4. Middle East & Africa Statin Market Forecast, By Drug Class 14.4.1. Astrovastatin 14.4.2. Fluvastatin 14.4.3. Lovastatin 14.4.4. Pravastatin 14.4.5. Simvastatin 14.4.6. Others 14.5. Middle East & Africa Statin Market Value Share Analysis, By Therapeutic Treatment 14.6. Middle East & Africa Statin Market Forecast, By Therapeutic Treatment 14.6.1. Cardiovascular disorders 14.6.2. Obesity 14.6.3. Inflammatory disorders 14.6.4. Others 14.7. Middle East & Africa Statin Market Value Share Analysis, By End User 14.8. Middle East & Africa Statin Market Forecast, By End User 14.8.1. Hospital 14.8.2. Clinics 14.9. Middle East & Africa Statin Market Value Share Analysis, by Country 14.10. Middle East & Africa Statin Market Forecast, by Country 14.10.1. GCC Countries 14.10.2. South Africa 14.10.3. Nigeria 14.10.4. Egypt 14.11. Middle East & Africa Statin Market Analysis, by Country 14.12. GCC Statin Market Forecast, By Drug Class 14.12.1. Astrovastatin 14.12.2. Fluvastatin 14.12.3. Lovastatin 14.12.4. Pravastatin 14.12.5. Simvastatin 14.12.6. Others 14.13. GCC Statin Market Forecast, By Therapeutic Treatment 14.13.1. Cardiovascular disorders 14.13.2. Obesity 14.13.3. Inflammatory disorders 14.13.4. Others 14.14. GCC Statin Market Forecast, By End User 14.14.1. Hospital 14.14.2. Clinics 14.15. South Africa Statin Market Forecast, By Drug Class 14.15.1. Astrovastatin 14.15.2. Fluvastatin 14.15.3. Lovastatin 14.15.4. Pravastatin 14.15.5. Simvastatin 14.15.6. Others 14.16. South Africa Statin Market Forecast, By Therapeutic Treatment 14.16.1. Cardiovascular disorders 14.16.2. Obesity 14.16.3. Inflammatory disorders 14.16.4. Others 14.17. South Africa Statin Market Forecast, By End User 14.17.1. Hospital 14.17.2. Clinics 14.18. Nigeria Statin Market Forecast, By Drug Class 14.18.1. Astrovastatin 14.18.2. Fluvastatin 14.18.3. Lovastatin 14.18.4. Pravastatin 14.18.5. Simvastatin 14.18.6. Others 14.19. Nigeria Statin Market Forecast, By Therapeutic Treatment 14.19.1. Cardiovascular disorders 14.19.2. Obesity 14.19.3. Inflammatory disorders 14.19.4. Others 14.20. Nigeria Statin Market Forecast, By End User 14.20.1. Hospital 14.20.2. Clinics 14.21. Egypt Statin Market Forecast, By Drug Class 14.21.1. Astrovastatin 14.21.2. Fluvastatin 14.21.3. Lovastatin 14.21.4. Pravastatin 14.21.5. Simvastatin 14.21.6. Others 14.22. Egypt Statin Market Forecast, By Therapeutic Treatment 14.22.1. Cardiovascular disorders 14.22.2. Obesity 14.22.3. Inflammatory disorders 14.22.4. Others 14.23. Egypt Statin Market Forecast, By End User 14.23.1. Hospital 14.23.2. Clinics 14.24. Middle East & Africa Statin Market Attractiveness Analysis 14.24.1. By Drug Class 14.24.2. By Therapeutic Treatment 14.24.3. By End User 14.25. PEST Analysis 14.26. Key Trends 14.27. Key Developments 15. South America Statin Market Analysis 15.1. Key Findings 15.2. South America Statin Market Overview 15.3. South America Statin Market Value Share Analysis, By Drug Class 15.4. South America Statin Market Forecast, By Drug Class 15.4.1. Astrovastatin 15.4.2. Fluvastatin 15.4.3. Lovastatin 15.4.4. Pravastatin 15.4.5. Simvastatin 15.4.6. Others 15.5. South America Statin Market Value Share Analysis, By Therapeutic Treatment 15.6. South America Statin Market Forecast, By Therapeutic Treatment 15.6.1. Cardiovascular disorders 15.6.2. Obesity 15.6.3. Inflammatory disorders 15.6.4. Others 15.7. South America Statin Market Value Share Analysis, By End User 15.8. South America Statin Market Forecast, By End User 15.8.1. Hospital 15.8.2. Clinics 15.9. South America Statin Market Value Share Analysis, by Country 15.10. South America Statin Market Forecast, by Country 15.10.1. Mexico 15.10.2. Brazil 15.10.3. Argentina 15.11. South America Statin Market Analysis, by Country 15.12. Brazil Statin Market Forecast, By Drug Class 15.12.1. Astrovastatin 15.12.2. Fluvastatin 15.12.3. Lovastatin 15.12.4. Pravastatin 15.12.5. Simvastatin 15.12.6. Others 15.13. Brazil Statin Market Forecast, By Therapeutic Treatment 15.13.1. Cardiovascular disorders 15.13.2. Obesity 15.13.3. Inflammatory disorders 15.13.4. Others 15.14. Brazil Statin Market Forecast, By End User 15.14.1. Hospital 15.14.2. Clinics 15.15. Mexico Statin Market Forecast, By Drug Class 15.15.1. Astrovastatin 15.15.2. Fluvastatin 15.15.3. Lovastatin 15.15.4. Pravastatin 15.15.5. Simvastatin 15.15.6. Others 15.16. Mexico Statin Market Forecast, By Therapeutic Treatment 15.16.1. Cardiovascular disorders 15.16.2. Obesity 15.16.3. Inflammatory disorders 15.16.4. Others 15.17. Mexico Statin Market Forecast, By End User 15.17.1. Hospital 15.17.2. Clinics 15.18. Argentina Statin Market Forecast, By Drug Class 15.18.1. Astrovastatin 15.18.2. Fluvastatin 15.18.3. Lovastatin 15.18.4. Pravastatin 15.18.5. Simvastatin 15.18.6. Others 15.19. Argentina Statin Market Forecast, By Therapeutic Treatment 15.19.1. Cardiovascular disorders 15.19.2. Obesity 15.19.3. Inflammatory disorders 15.19.4. Others 15.20. Argentina Statin Market Forecast, By End User 15.20.1. Hospital 15.20.2. Clinics 15.21. South America Statin Market Attractiveness Analysis 15.21.1. By Drug Class 15.21.2. By Therapeutic Treatment 15.21.3. By End User 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 16.2.2. New Therapeutic Treatment Launches and Therapeutic Treatment Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Abbott 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Therapeutic Treatment Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. AstraZeneca 16.3.3. Aurobindo Pharma 16.3.4. Biocon 16.3.5. GlaxoSmithKline 16.3.6. Merck & Co. 16.3.7. Novartis 16.3.8. Pfizer 17. Primary Key Insights